Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Altamira TherapeuticsCYTOF +0.63% 3-Year EBITDA Growth Rate is 76.40% as of Jun. 2025, which is 9% above its 10-year median of 70.20. The stock has 4 warning signs investors should review. Among 1,130 Biotechnology companies, Altamira Therapeutics ranks better than 95.31% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 76.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 68.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Altamira Therapeutics was 76.40% per year. The lowest was 26.20% per year. And the median was 70.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Altamira Therapeutics 3-Year EBITDA Growth Rate Related Terms
CYTOF vs CARM, PTIX, SIGY: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Altamira Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Altamira Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Altamira Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Altamira Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 76.40% mean?
Altamira Therapeutics (CYTOF) has a 3-Year EBITDA Growth Rate of 76.40% as of Jun. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Altamira Therapeutics and its competitors. This is near median its historical median of 70.20. Over the past decade, Altamira Therapeutics' 3-Year EBITDA Growth Rate has ranged from 26.20 to 76.40. According to the industry distribution chart, Altamira Therapeutics ranks #53 out of 1130 companies in the Biotechnology industry, placing it in the top 4.7%.
Is Altamira Therapeutics' 3-Year EBITDA Growth Rate too high?
Altamira Therapeutics' current 3-Year EBITDA Growth Rate of 76.40% is near median its 10-year median of 70.20. Over the past 10 years, this metric has ranged from a low of 26.20 to a high of 76.40. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Altamira Therapeutics' value of 76.40% is 414.5% above this industry median. Based on the distribution chart, Altamira Therapeutics ranks #53 out of 1130 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Altamira Therapeutics' 3-Year EBITDA Growth Rate compare to CARM and PTIX?
According to the Biotechnology industry distribution chart, Altamira Therapeutics ranks #53 out of 1130 companies for 3-Year EBITDA Growth Rate. This places Altamira Therapeutics in the top 5% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.85. Altamira Therapeutics' value of 76.40% is 414.5% above this benchmark. Historically, Altamira Therapeutics' own 3-Year EBITDA Growth Rate has ranged from 26.20 to 76.40 over the past decade. While the company's 10-year median is 70.20 vs. the industry median of 14.85, Altamira Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Altamira Therapeutics's current 3-Year EBITDA Growth Rate of 76.40% is 414.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Altamira Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Altamira Therapeutics's current 3-Year EBITDA Growth Rate is 76.40%, which is near median its own 10-year median of 70.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Altamira Therapeutics stock overvalued right now?
Altamira Therapeutics (CYTOF) has a current 3-Year EBITDA Growth Rate of 76.40%. The current 3-Year EBITDA Growth Rate is 76.40%, which is near median its 10-year median of 70.20 and 414.5% above the Biotechnology industry median of 14.85. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Altamira Therapeutics (CYTOF), the current 3-Year EBITDA Growth Rate is 76.40% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Altamira Therapeutics Ltd is developing and supplying peptide-based nanoparticles for safe and effective RNA delivery to extrahepatic tissues (xPhore platform). The Company is offering biopharmaceutical companies access to its technology for use with their own RNA molecules under collaboration and licensing agreements. The xPhore platform is suitable for various RNA modalities - OligoPhore for oligonucleotides, SemaPhore for mRNA, CycloPhore for circRNA - as well as for DNA (GenePhore). In addition, Altamira Therapeutics is pursuing two proprietary flagship development programs using OligoPhore: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. Geographically, the companies operates in United Staes and Switzerland.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CYTOF has been successfully added to your 
